Anktiva (N-803)

Category: compound

An IL-15 superagonist that activates NK cells and CD8+ T cells. FDA-approved for bladder cancer, being studied across multiple advanced cancers.

Mechanism Detail

N-803 is an IL-15/IL-15Rα-Fc fusion protein that trans-presents IL-15 to NK cells and CD8+ T cells. It drives proliferation of cytotoxic lymphocytes, enhances ADCC, and reinvigorates exhausted T cells in the tumor microenvironment. Synergizes with PD-1/PD-L1 blockade.

Clinical Status

FDA-approved for BCG-unresponsive bladder cancer (2024). Phase II/III trials ongoing for NSCLC, pancreatic, and other solid tumors.

Relevant Diseases

• Stage IV Cancer

Relevant Therapies

• Anktiva
• Cell-Based Therapies

Related Terms

• IL-15
• NK cells
• Checkpoint inhibitors
• Immunotherapy